GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO
GlaxoSmithKline Pharmaceuticals Ltd
Pre-Tax Income
GlaxoSmithKline Pharmaceuticals Ltd
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO
|
Pre-Tax Income
₹11.7B
|
CAGR 3-Years
30%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Pre-Tax Income
₹72.8B
|
CAGR 3-Years
26%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Pre-Tax Income
₹65.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
23%
|
CAGR 10-Years
15%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Pre-Tax Income
₹133.1B
|
CAGR 3-Years
21%
|
CAGR 5-Years
21%
|
CAGR 10-Years
6%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Pre-Tax Income
₹26.4B
|
CAGR 3-Years
16%
|
CAGR 5-Years
29%
|
CAGR 10-Years
9%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Pre-Tax Income
₹24B
|
CAGR 3-Years
12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
GlaxoSmithKline Pharmaceuticals Ltd
Glance View
GlaxoSmithKline Pharmaceuticals Ltd., a subsidiary of the global healthcare juggernaut GSK, stands as a pillar in the pharmaceutical industry, with roots deeply entrenched in innovation and a robust pipeline of healthcare products. This company weaves a narrative of relentless pursuit in the creation and distribution of a wide variety of medicines and vaccines, aimed at improving the quality of human life. Operating predominantly in the areas of pharmaceuticals, vaccines, and consumer healthcare, GSK integrates cutting-edge research with strategic collaborations. This enables them to address pressing medical needs, such as respiratory diseases, HIV, infectious diseases, and oncology, amongst others, thereby leveraging their expertise to cater to diverse healthcare demands. The heart of their revenue generation lies in the seamless amalgamation of research acumen and market presence. By investing significantly in research and development, GSK continually introduces groundbreaking therapies and health solutions. The company has adeptly structured its operations to create a strong global presence, which not only involves selling directly to healthcare providers and governments but also innovating its supply chain to maximize reach. Moreover, GSK's astute marketing efforts ensure that their products are not just effective but also attuned to consumer needs. With a focus on sustainable growth and transformative medicines, GSK’s story becomes a testament to how science-driven strategies can forge pathways to a healthier world while simultaneously fueling the company’s economic engine.
See Also
What is GlaxoSmithKline Pharmaceuticals Ltd's Pre-Tax Income?
Pre-Tax Income
11.7B
INR
Based on the financial report for Dec 31, 2024, GlaxoSmithKline Pharmaceuticals Ltd's Pre-Tax Income amounts to 11.7B INR.
What is GlaxoSmithKline Pharmaceuticals Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
27%
Over the last year, the Pre-Tax Income growth was 59%. The average annual Pre-Tax Income growth rates for GlaxoSmithKline Pharmaceuticals Ltd have been 30% over the past three years , 27% over the past five years .
You don't have any saved screeners yet